Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC).
The mTOR (mammalian target of rapamycin) signal transduction pathway integrates various signals, regulating ribosome biogenesis and protein synthesis as a function of available energy and amino acids, and assuring an appropriate coupling of cellular proliferation with increases in cell size. In addi...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-02-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3044148?pdf=render |
| _version_ | 1818616031189401600 |
|---|---|
| author | Daniele Campa Anika Hüsing Angelika Stein Lucie Dostal Heiner Boeing Tobias Pischon Anne Tjønneland Nina Roswall Kim Overvad Jane Nautrup Østergaard Laudina Rodríguez Núria Sala Maria-José Sánchez Nerea Larrañaga José María Huerta Aurelio Barricarte Kay-Tee Khaw Nicholas Wareham Ruth C Travis Naomi E Allen Pagona Lagiou Antonia Trichopoulou Dimitrios Trichopoulos Domenico Palli Sabina Sieri Rosario Tumino Carlotta Sacerdote Henk van Kranen H Bas Bueno-de-Mesquita Göran Hallmans Mattias Johansson Isabelle Romieu Mazda Jenab David G Cox Afshan Siddiq Elio Riboli Federico Canzian Rudolf Kaaks |
| author_facet | Daniele Campa Anika Hüsing Angelika Stein Lucie Dostal Heiner Boeing Tobias Pischon Anne Tjønneland Nina Roswall Kim Overvad Jane Nautrup Østergaard Laudina Rodríguez Núria Sala Maria-José Sánchez Nerea Larrañaga José María Huerta Aurelio Barricarte Kay-Tee Khaw Nicholas Wareham Ruth C Travis Naomi E Allen Pagona Lagiou Antonia Trichopoulou Dimitrios Trichopoulos Domenico Palli Sabina Sieri Rosario Tumino Carlotta Sacerdote Henk van Kranen H Bas Bueno-de-Mesquita Göran Hallmans Mattias Johansson Isabelle Romieu Mazda Jenab David G Cox Afshan Siddiq Elio Riboli Federico Canzian Rudolf Kaaks |
| author_sort | Daniele Campa |
| collection | DOAJ |
| description | The mTOR (mammalian target of rapamycin) signal transduction pathway integrates various signals, regulating ribosome biogenesis and protein synthesis as a function of available energy and amino acids, and assuring an appropriate coupling of cellular proliferation with increases in cell size. In addition, recent evidence has pointed to an interplay between the mTOR and p53 pathways. We investigated the genetic variability of 67 key genes in the mTOR pathway and in genes of the p53 pathway which interact with mTOR. We tested the association of 1,084 tagging SNPs with prostate cancer risk in a study of 815 prostate cancer cases and 1,266 controls nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). We chose the SNPs (n = 11) with the strongest association with risk (p<0.01) and sought to replicate their association in an additional series of 838 prostate cancer cases and 943 controls from EPIC. In the joint analysis of first and second phase two SNPs of the PRKCI gene showed an association with risk of prostate cancer (OR(allele) = 0.85, 95% CI 0.78-0.94, p = 1.3 x 10⁻³ for rs546950 and OR(allele) = 0.84, 95% CI 0.76-0.93, p = 5.6 x 10⁻⁴ for rs4955720). We confirmed this in a meta-analysis using as replication set the data from the second phase of our study jointly with the first phase of the Cancer Genetic Markers of Susceptibility (CGEMS) project. In conclusion, we found an association with prostate cancer risk for two SNPs belonging to PRKCI, a gene which is frequently overexpressed in various neoplasms, including prostate cancer. |
| first_indexed | 2024-12-16T16:43:20Z |
| format | Article |
| id | doaj.art-1cf180b3af0d4f95ad44b0b069afed00 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-16T16:43:20Z |
| publishDate | 2011-02-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-1cf180b3af0d4f95ad44b0b069afed002022-12-21T22:24:14ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-02-0162e1691410.1371/journal.pone.0016914Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC).Daniele CampaAnika HüsingAngelika SteinLucie DostalHeiner BoeingTobias PischonAnne TjønnelandNina RoswallKim OvervadJane Nautrup ØstergaardLaudina RodríguezNúria SalaMaria-José SánchezNerea LarrañagaJosé María HuertaAurelio BarricarteKay-Tee KhawNicholas WarehamRuth C TravisNaomi E AllenPagona LagiouAntonia TrichopoulouDimitrios TrichopoulosDomenico PalliSabina SieriRosario TuminoCarlotta SacerdoteHenk van KranenH Bas Bueno-de-MesquitaGöran HallmansMattias JohanssonIsabelle RomieuMazda JenabDavid G CoxAfshan SiddiqElio RiboliFederico CanzianRudolf KaaksThe mTOR (mammalian target of rapamycin) signal transduction pathway integrates various signals, regulating ribosome biogenesis and protein synthesis as a function of available energy and amino acids, and assuring an appropriate coupling of cellular proliferation with increases in cell size. In addition, recent evidence has pointed to an interplay between the mTOR and p53 pathways. We investigated the genetic variability of 67 key genes in the mTOR pathway and in genes of the p53 pathway which interact with mTOR. We tested the association of 1,084 tagging SNPs with prostate cancer risk in a study of 815 prostate cancer cases and 1,266 controls nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). We chose the SNPs (n = 11) with the strongest association with risk (p<0.01) and sought to replicate their association in an additional series of 838 prostate cancer cases and 943 controls from EPIC. In the joint analysis of first and second phase two SNPs of the PRKCI gene showed an association with risk of prostate cancer (OR(allele) = 0.85, 95% CI 0.78-0.94, p = 1.3 x 10⁻³ for rs546950 and OR(allele) = 0.84, 95% CI 0.76-0.93, p = 5.6 x 10⁻⁴ for rs4955720). We confirmed this in a meta-analysis using as replication set the data from the second phase of our study jointly with the first phase of the Cancer Genetic Markers of Susceptibility (CGEMS) project. In conclusion, we found an association with prostate cancer risk for two SNPs belonging to PRKCI, a gene which is frequently overexpressed in various neoplasms, including prostate cancer.http://europepmc.org/articles/PMC3044148?pdf=render |
| spellingShingle | Daniele Campa Anika Hüsing Angelika Stein Lucie Dostal Heiner Boeing Tobias Pischon Anne Tjønneland Nina Roswall Kim Overvad Jane Nautrup Østergaard Laudina Rodríguez Núria Sala Maria-José Sánchez Nerea Larrañaga José María Huerta Aurelio Barricarte Kay-Tee Khaw Nicholas Wareham Ruth C Travis Naomi E Allen Pagona Lagiou Antonia Trichopoulou Dimitrios Trichopoulos Domenico Palli Sabina Sieri Rosario Tumino Carlotta Sacerdote Henk van Kranen H Bas Bueno-de-Mesquita Göran Hallmans Mattias Johansson Isabelle Romieu Mazda Jenab David G Cox Afshan Siddiq Elio Riboli Federico Canzian Rudolf Kaaks Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC). PLoS ONE |
| title | Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC). |
| title_full | Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC). |
| title_fullStr | Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC). |
| title_full_unstemmed | Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC). |
| title_short | Genetic variability of the mTOR pathway and prostate cancer risk in the European Prospective Investigation on Cancer (EPIC). |
| title_sort | genetic variability of the mtor pathway and prostate cancer risk in the european prospective investigation on cancer epic |
| url | http://europepmc.org/articles/PMC3044148?pdf=render |
| work_keys_str_mv | AT danielecampa geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT anikahusing geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT angelikastein geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT luciedostal geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT heinerboeing geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT tobiaspischon geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT annetjønneland geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT ninaroswall geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT kimovervad geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT janenautrupøstergaard geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT laudinarodriguez geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT nuriasala geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT mariajosesanchez geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT nerealarranaga geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT josemariahuerta geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT aureliobarricarte geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT kayteekhaw geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT nicholaswareham geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT ruthctravis geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT naomieallen geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT pagonalagiou geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT antoniatrichopoulou geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT dimitriostrichopoulos geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT domenicopalli geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT sabinasieri geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT rosariotumino geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT carlottasacerdote geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT henkvankranen geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT hbasbuenodemesquita geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT goranhallmans geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT mattiasjohansson geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT isabelleromieu geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT mazdajenab geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT davidgcox geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT afshansiddiq geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT elioriboli geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT federicocanzian geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic AT rudolfkaaks geneticvariabilityofthemtorpathwayandprostatecancerriskintheeuropeanprospectiveinvestigationoncancerepic |